Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy
| Autor: | Mustafa Yilmaz, Dincer Yildizdas, Osman Küçükosmanoğlu, Bilgin Yüksel, Sevcan Erdem |
|---|---|
| Přispěvatelé: | Çukurova Üniversitesi |
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Neutropenia Hypertension Pulmonary Vasodilator Agents medicine.medical_treatment Hemodynamics Pulmonary hypertension Internal medicine White blood cell medicine Diazoxide Humans Pharmacology (medical) Respiratory system Children Heart Failure Mechanical ventilation business.industry Infant General Medicine medicine.disease medicine.anatomical_structure Heart failure Cardiology Congenital Hyperinsulinism Female business medicine.drug |
| Zdroj: | Advances in Therapy. 25:515-519 |
| ISSN: | 1865-8652 0741-238X |
| DOI: | 10.1007/s12325-008-0049-3 |
| Popis: | PubMedID: 18512033 Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical symptoms that occur when blood glucose levels drop below the normal range. Diazoxide treatment remains the mainstay of medical therapy. Tolerance of diazoxide is usually excellent, but several side effects of this drug have been described. We present a 4-month-old girl who developed pulmonary hypertension, heart failure and neutropenia during diazoxide therapy. Diazoxide toxicity was suspected and the drug was withdrawn on day 13. During the next 3 days, respiratory and haemodynamic status dramatically improved and she was weaned from mechanical ventilation. Control white blood cell count was 8800 cells/ mm 3 and a new echocardiography showed modreduction of pulmonary artificial pressure to 20 mmHg and resolution of atrial and ventricular enlargement. Paediatric physicians should be in mind of pulmonary hypertension, heart failure and neutropenia developing during diazoxide therapy. © Springer Healthcare Communications 2008. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink